ICON Selected by Roche for Technology Partnership
05 Mars 2012 - 12:32PM
Business Wire
ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global
provider of outsourced development services to the pharmaceutical,
biotechnology and medical device industries, today announced that
it has been selected by Roche as its technology partner for storing
and managing medical images collected during the company’s clinical
research programs.
Roche is using ICON’s MIRA™ (Medical Image Review and Analysis)
software as the company’s central repository for medical images.
MIRA is the core application used by ICON Medical Imaging in its
daily operations and provides functionality for imaging and
clinical data management, image analysis, project management and
document management. MIRA™ is being implemented by Roche in a
Software as a Service (SaaS) model, which provides Roche with 24/7
access to imaging data from anywhere in the world and also
eliminates the technology costs associated with purchasing and
maintaining an image management system in-house. ICON is the first
medical imaging provider to offer clients a SaaS solution for their
image management needs.
Commenting on the partnership, Dr. Gudrun Zahlman, Leader
Imaging Infrastructure at Roche, commented, “We committed to ICON
and MIRA after a one year pilot program. The comprehensive
functionality of MIRA, the US and EU redundancy of the data, and
the responsive nature of the ICON staff, proved the best fit
for Roche’s needs. Additionally, we have achieved the seamless
integration of images hosted in MIRA with Roche’s clinical data
repository and data mining tools for trial decision making, and
have integrated 3rd party image analysis software within MIRA for
quantitative biomarker research.”
“We are delighted to have been selected as a technology partner
by the Roche informatics team and to be involved with such a
collaborative and forward-thinking group,” commented Andrew Kraus,
Executive Vice President and CTO at ICON Medical Imaging. “MIRA’s
superior imaging capabilities, and fault tolerance mechanisms, made
it an ideal solution to offer clients in a SaaS framework. MIRA’s
extensible architecture also enables plug-in modules for advanced
analysis. Today’s announcement is another good example of the
innovation that ICON is bringing to the drug development process
and we look forward to building on our close technology partnership
with Roche.”
About ICON plc
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The Company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. ICON currently
has around 8,600 employees, operating from 84 locations in 40
countries.
Further information is available at www.iconplc.com
DISCLOSURE NOTICE: This release contains, and our
officers and representatives may from time to time make,
"forward-looking statements" within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such
as: "anticipate," "intend," "plan," "expect," "strategy" and
similar references to future periods. Forward-looking statements
are neither historical facts nor assurances of future performance.
Instead, they are based only on our current beliefs, expectations
and assumptions regarding the future of our business, future plans
and strategies, anticipated events and trends, the economy and
other future conditions. Because forward-looking statements relate
to the future, they are subject to inherent uncertainties, risks
and changes in circumstances that are difficult to predict and many
of which are outside of our control. Our actual results may differ
materially from those indicated in the forward-looking statements.
Therefore, you should not rely on any of these forward-looking
statements. Important factors that could cause our actual results
to differ materially from those indicated in the forward-looking
statements include, among others, strategic actions, including our
success in integrating PriceSpective; general economic and
financial conditions; the extent to which we are successful in
implementing our strategy, gaining new, long-term relationships
with customers and retaining existing ones; the risk of competition
on our industry; developments and changes in laws and regulations;
and such other factors as discussed in Part I, Item 3 “Risk
Factors” in our Form 20-F for the fiscal year ended December 31,
2010. Any forward-looking statement made by us in this release is
based only on information currently available to us and speaks only
as of the date on which it is made. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
ICON/ICLR-G
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024